ZA202402459B - Compounds for regulating trained immunity, and their methods of use - Google Patents

Compounds for regulating trained immunity, and their methods of use

Info

Publication number
ZA202402459B
ZA202402459B ZA2024/02459A ZA202402459A ZA202402459B ZA 202402459 B ZA202402459 B ZA 202402459B ZA 2024/02459 A ZA2024/02459 A ZA 2024/02459A ZA 202402459 A ZA202402459 A ZA 202402459A ZA 202402459 B ZA202402459 B ZA 202402459B
Authority
ZA
South Africa
Prior art keywords
compounds
regulating
methods
trained immunity
immunity
Prior art date
Application number
ZA2024/02459A
Other languages
English (en)
Inventor
Henricus Marie Janssen
Freek Johannes Maria Hoeben
Bas Van Genabeek
Serge Hendrikus Mathijs Sontjens
Willem M J Mulder
Original Assignee
Trained Therapeutix Discovery Inc
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trained Therapeutix Discovery Inc, Icahn School Med Mount Sinai filed Critical Trained Therapeutix Discovery Inc
Publication of ZA202402459B publication Critical patent/ZA202402459B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2024/02459A 2021-03-19 2024-03-27 Compounds for regulating trained immunity, and their methods of use ZA202402459B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163163428P 2021-03-19 2021-03-19

Publications (1)

Publication Number Publication Date
ZA202402459B true ZA202402459B (en) 2024-08-28

Family

ID=83321251

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/02459A ZA202402459B (en) 2021-03-19 2024-03-27 Compounds for regulating trained immunity, and their methods of use

Country Status (14)

Country Link
US (2) US11859021B2 (https=)
EP (1) EP4308105A4 (https=)
JP (1) JP7824314B2 (https=)
KR (1) KR20230171435A (https=)
CN (2) CN118459539B (https=)
AU (1) AU2022239614A1 (https=)
BR (1) BR112023018950A2 (https=)
CA (1) CA3212571A1 (https=)
CL (1) CL2023002783A1 (https=)
CO (1) CO2023013700A2 (https=)
IL (1) IL306006A (https=)
MX (1) MX2023011004A (https=)
WO (1) WO2022198101A1 (https=)
ZA (1) ZA202402459B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
JP2024512501A (ja) 2021-03-19 2024-03-19 アルヴィナス・オペレーションズ・インコーポレイテッド インダゾール系化合物及び関連使用方法
WO2025089217A1 (ja) * 2023-10-23 2025-05-01 株式会社ヤクルト本社 γ－Ｄ－グルタミル－Ｌ－リシルエンドペプチダーゼの活性を評価するための基質として用いられる化合物

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138436A (en) 1978-02-24 1982-12-28 Gerhard Baschang Process for the manufacture of novel antigens
JPS5528933A (en) 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
JPS5618996A (en) 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
JPS58172399A (ja) 1982-04-05 1983-10-11 Dai Ichi Seiyaku Co Ltd ムラミルトリペプチド誘導体
EP0102319B1 (de) 1982-07-23 1987-08-19 Ciba-Geigy Ag Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen
FI852105L (fi) 1984-05-29 1985-11-30 Ciba Geigy Ag Acylerade sockerderivat, foerfarande foer deras framstaellning och deras anvaendning.
JPS6157597A (ja) 1984-08-29 1986-03-24 Toshiyuki Hamaoka ムラミルペプチド活性エステル誘導体
EP0192611A3 (de) 1985-02-20 1988-05-11 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
EP0192609A3 (de) 1985-02-20 1988-04-27 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
US4640911A (en) 1985-05-29 1987-02-03 Ciba-Geigy Corporation Acylated sugar derivatives, processes for their manufacture, and their use
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5506204A (en) 1991-11-19 1996-04-09 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5349060A (en) 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
GB9413935D0 (en) 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
GB9618673D0 (en) 1996-09-06 1996-10-16 Peptech Uk Ltd The use of muramyl peptides
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
JP4224115B2 (ja) 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP2009504192A (ja) 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
CA2683063A1 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101096386A (zh) 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US7928100B2 (en) 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
EP2217221B1 (en) 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
CN105903029A (zh) 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
CN102264364B (zh) * 2008-10-22 2014-06-18 康奈尔大学 一种多环化合物及其相关方法
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2620156B1 (en) 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
US20140086839A1 (en) 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
CN102178954B (zh) 2011-04-25 2014-05-28 中国药科大学 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013192310A1 (en) 2012-06-19 2013-12-27 Massachusetts Institute Of Technology Mass production and size control of nanoparticles through controlled microvortices
EP2703384A1 (en) 2012-08-27 2014-03-05 Ludwig-Maximilians-Universität München Inhibitors of CD40-TRAF6 interaction
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
CN103589699B (zh) * 2013-11-05 2015-05-13 江南大学 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
US11642419B2 (en) 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
ES2819473T3 (es) 2015-04-20 2021-04-16 Memorial Sloan Kettering Cancer Center Obtención de imágenes de macrófagos asociados a tumor
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
BR112018000217A2 (pt) 2015-07-15 2018-09-04 Celator Pharmaceuticals Inc sistemas de distribuição de nanopartículas aperfeiçoados
US20180221289A1 (en) 2015-08-06 2018-08-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods
US20190008918A1 (en) 2016-03-08 2019-01-10 Bioxcel Corporation Immunomodulation therapies for cancer
CN109640959B (zh) * 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
WO2018071549A1 (en) 2016-10-11 2018-04-19 New York University Nanoparticles and uses thereof
CN106831614B (zh) * 2017-01-09 2020-07-28 清华大学 取代的苯并二氮杂环类化合物及其制备方法和用途
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
AU2018370237B2 (en) 2017-11-20 2024-10-17 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
EP3713548A4 (en) 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions

Also Published As

Publication number Publication date
BR112023018950A2 (pt) 2024-02-27
MX2023011004A (es) 2024-01-08
JP7824314B2 (ja) 2026-03-04
JP2024511067A (ja) 2024-03-12
US20240190921A1 (en) 2024-06-13
EP4308105A1 (en) 2024-01-24
AU2022239614A1 (en) 2023-10-12
CN118459539A (zh) 2024-08-09
CN117355298A (zh) 2024-01-05
US11859021B2 (en) 2024-01-02
CL2023002783A1 (es) 2024-03-22
CN118459539B (zh) 2026-01-06
EP4308105A4 (en) 2025-03-12
US20220332762A1 (en) 2022-10-20
CO2023013700A2 (es) 2024-02-26
CA3212571A1 (en) 2022-09-22
KR20230171435A (ko) 2023-12-20
WO2022198101A1 (en) 2022-09-22
IL306006A (en) 2023-11-01
AU2022239614A9 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
ZA202402459B (en) Compounds for regulating trained immunity, and their methods of use
MY209340A (en) Egfr inhibitor for the treatment of cancer
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
EP4474017A3 (en) New heterocyclic compounds
CR20230496A (es) Compuestos heterocíclicos
MX2020011183A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
ZA202308002B (en) Pyrimidopyran compound
PH12022550433A1 (en) Heterocyclic compounds
MX2023002525A (es) Nuevos compuestos.
PH12023553237A1 (en) Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
ZA202101487B (en) Novel compounds
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
PH12013501140A1 (en) Photochromic compounds, compositions and articles
ZA202301378B (en) Solid form of compound
EP4643954A3 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
PH12021553249A1 (en) New heterocyclic compounds
ZA202500287B (en) Crystalline forms of 1,2,4-oxadiazole fungicides
WO2021094505A8 (en) Herbicidal compounds
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MX2025007548A (es) Pirroloquinazolinonas espirociclicas sustituidas y piperidinoquinazolinonas espirociclicas sustituidas
PH12022551955A1 (en) Novel compound
PH12021552787A1 (en) Tetracyclic compounds as cdc7 inhibitors